Recursion Announces First Patient Dosed In Phase 2 Clinical Study Of REC-3964, A Potential First-in-class, Oral, Non-antibiotic Small Molecule For Recurrent Clostridioides Difficile Infection
SALT LAKE CITY, Oct 23 (Bernama-GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically…


